Hyperlipidemia and fibrates: Focus on diabetes;Hyperlipidämie und fibrate unter besonderer berücksichtigung des diabetes

Herz

Volumn 26, Issue 8, 2001, Pages 523-530

  Henkel, Elena ^a   Hanefeld, Markolf ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Atherosclerosis; Dyslipidemia; Fibrates; Risk factors; Type 2 diabetes

Indexed keywords

ANTILIPEMIC AGENT; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN; LIPID; LOW DENSITY LIPOPROTEIN; STATIN;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DISEASE ASSOCIATION; DOSE RESPONSE; HIGH RISK POPULATION; HUMAN; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; METABOLISM; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN DEGRADATION; RISK FACTOR;

EID: 0035673723     PISSN: 03409937     EISSN: None     Source Type: Journal    
DOI: 10.1007/PL00002057     Document Type: Article

References (30)

1. Diabetes mellitus and hypertension in the elderly: Concomitant hyperlipidemia and coronary heart disease risk
2. Risk factors for myocardial infarction and death in newly detected NIDDM: The diabetes intervention study, 11-year follow-up
3. Reduction of mortality in the stockholm ischaemic heart disease secondary prevention study by combined treatment with clofibrate and nicotinic acid
4. Relation of triglyceride metabolism and coronary artery disease. Studies in the postprandial state
5. Differences in postprandial lipemia between patients with normal glucose tolerance and NIDDM
6. Postprandial lipid metabolism and ß-cell function in non-insulin-dependent (type 2) diabetes mellitus after a mixed meal with a high fat content
7. Postprandial lipoprotein metabolism in normal and obese subjects: Comparison after the vitamin A fatloading test
8. Abnormal metabolism of postprandial lipoproteins in patients with non-insulin-dependent diabetes mellitus is not related to coronary artery disease
9. Impaired glucose tolerance is not associated with lipid intolerance
10. Insulin resistance is associated with lipid and lipoprotein abnormalities in subjects with varying degrees of glucose tolerance
11. Effect of oral antidiabetics and insulin on lipids and coronary heart disease in non-insulin-dependent diabetes mellitus
12. Risikofaktoren- und stoffwechselkontrolle: Was, wann und wie?
13. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance
14. Epidemiology of insulin resistance and its relation to coronary disease
15. The diabetes atherosclerosis intervention study (DIAS): A study conducted in cooperation with the world health organization
16. The role of fibric acids in atherosclerosis
17. Postprandial lipemia, fenofibrate and coronary heart disease
18. Ciprofibrate therapy reduces postprandial lipaemia and improves endothelial function in NIDDM. Am diabet assoc 59th sci session
19. Effect of etofibrate (LipoMerz) on plasma insulin levels and glucose tolerance in hypertriglyceridemic patients with multiple dysmetabolism
20. Differential diagnosis and differential treatment of carbohydrate tolerance disorders in patients with hyperlipoproteinemia
21. Therapeutische anwendung der statine
22. Fenofibrate decreases plasma fibrinogen, improves lipid profile, and reduces uricemia
23. Fibrinolytic proteins and progression of coronary artery disease in relation to gemfibrozil therapy
24. Lipid changes of fibrinogen and of platelet aggregation induced by etofibrate
25. Cardiovascular outcomes in type 2 diabetes. A double blind placebo controlled study of bezafibrate: The St. Mary's, ealing, northwick park diabetes cardiovascular disease prevention (SENDCAP) study
26. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol
27. Helsinki heart study: Primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia
28. Predicting risk reduction of coronary disease in patients who are glucose intolerant: A comparison of treatment with fenofibrate and other lipid-modifying agents
29. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: The diabetes atherosclerosis intervention study, a randomised study
30. Diabetes: Statins, fibrates, or both?